Aatorvastatin effect on lung function and serum level of hs-CRP in chemical warfare patients with obstructive pulmonary disease.

Atorvastatin effect on lung function and serum level of hs-CRP in chemical warfare patients with obstructive pulmonary disease.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT201101095579N1

Enrollment

Registered

2011-11-13

Start date

2011-02-04

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic obstructive pulmonary disease. Chronic lower respiratory diseases

Interventions

Intervention 1: In intervention group: Atorvastatin, 40 mg tablet, once daily for 9 weeks. Intervention 2: In control group: The placebo tablet, once daily for 9 weeks.

Treatment - Drugs

Placebo

In intervention group: Atorvastatin, 40 mg tablet, once daily for 9 weeks

In control group: The placebo tablet, once daily for 9 weeks

Eligibility

Sex/Gender

Male

Age

35 Years to 85 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: Chemical warfare victims with obstructive pulmonary disease; age between 35-85; clinically stable disease in previous 8 weeks; acceptance of study design by patients. Exclusion criteria: Active infectious disease; bronchiectasis; chronic inflammatory diseases; soft tissue diseases; active liver and kidney diseases; cancer; cardiac disease (myocardial infarction and unstable angina in previous 6 months); sensitivity to atorvastatin; myopathy; myositis; hypercholestrolemia history; history of atorvastatin consumption; history of smoking; asthma; elevated CPK and elevated liver function test more than twice.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
COPD Assessment Test (CAT) questionnaire. Timepoint: At the beginning of study and 9 weeks after intervention. Method of measurement: CAT questionnaire score (score from 0 to 40).;Six Minute Walk Distance Test (6MWDT). Timepoint: At the beginning of study, 4 weeks and 9 weeks after intervention. Method of measurement: Distance walked in six minute (Meter).;Pulmonary volumes. Timepoint: At the beginning of study, 4 weeks and 9 weeks after intervention. Method of measurement: Spirometry.;The level of hs-CRP. Timepoint: At the beginnig of study and 9 weeks after intervention. Method of measurement: Laboratory.;St. George Respiratory Questionnaire. Timepoint: At the beginning of study and 9 weeks after intervention. Method of measurement: The questionnaire of assessing symptoms score, activity score, impact score and total score.	—

Measure

Time frame

COPD Assessment Test (CAT) questionnaire. Timepoint: At the beginning of study and 9 weeks after intervention. Method of measurement: CAT questionnaire score (score from 0 to 40).;Six Minute Walk Distance Test (6MWDT). Timepoint: At the beginning of study, 4 weeks and 9 weeks after intervention. Method of measurement: Distance walked in six minute (Meter).;Pulmonary volumes. Timepoint: At the beginning of study, 4 weeks and 9 weeks after intervention. Method of measurement: Spirometry.;The level of hs-CRP. Timepoint: At the beginnig of study and 9 weeks after intervention. Method of measurement: Laboratory.;St. George Respiratory Questionnaire. Timepoint: At the beginning of study and 9 weeks after intervention. Method of measurement: The questionnaire of assessing symptoms score, activity score, impact score and total score.

—

Secondary

Measure	Time frame
O2 saturation of arterial blood. Timepoint: At the beginning of study, 4 weeks and 9 weeks after intervention. Method of measurement: Pulse oximetry device.;Atorvastatin side effects. Timepoint: 4 weeks and 9 weeks after intervention. Method of measurement: According to patient symptoms.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAfsoun Mahmoudpour

Ardabil University Of Medical Sciences

Mahmoudpour.afsoun@gmail.com+98 45 1551 2006

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026